Semax Nasal

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four building blocks come from the hormone ACTH (fragment 4 to 10), the Pro-Gly-Pro tail was added so that enzymes do not take the molecule apart right away. Unlike full-length ACTH, this fragment does not drive the adrenal gland, so it has no hormonal effect on cortisol and acts directly in the nervous system instead. Semax was developed at the Institute of Molecular Genetics in Moscow and has been approved in Russia as nasal drops since the 1990s, at low concentration for attention and fatigue complaints, at high concentration around stroke.

This variant is the ready-made nasal spray: 10mg of Semax dissolved in 5ml of saline plus 0.4ml of bacteriostatic water, 5.4ml in total, which gives 1.85mg per ml. The pump delivers 0.1ml per spray, so about 0.185mg or 185mcg. That works out to 54 sprays on paper, about 50 once the pump is primed. No mixing, no syringes, no conversions, the spray is made fresh after your order and ships as an express item. If you prefer working with the vial, the Semax vial entry has the calculator and the notes on subcutaneous use.

With Semax the nose is not a workaround but the original route: practically all Russian studies, from the BDNF animal work to the stroke patient trials, gave Semax nasally. That makes Semax one of the few peptides where nasal dosing has actually been studied rather than being extrapolated from the syringe.

This information is for research and educational purposes only. No medical advice.

The best-documented pathway runs through the nerve growth factors. Dolotov and colleagues (Brain Research 2006) gave rats a single nasal dose of 50mcg per kg and found, within a few hours, three times the BDNF mRNA, 1.4 times the BDNF protein and a stronger activation of its receptor TrkB in the hippocampus, the hub for learning and memory. In parallel the animals learned an avoidance task better. BDNF is the messenger that helps nerve cells build new connections and protects them from damage, which is why this finding fits both uses, the nootropic one and the protective one after circulatory damage.

Semax also reaches into the monoamine systems. In rodent studies serotonin turnover in the striatum rises after Semax. Dopamine-dependent effects are amplified, although Semax on its own does not raise dopamine levels. On top of that come inflammation-modulating effects at the gene level, studied mainly in stroke models. The breakdown product Pro-Gly-Pro is not inert either, it belongs to the glyprolines, which show neuroprotective properties of their own, so Semax partly keeps acting through its own fragments.

In everyday research use people mainly report clearer focus, less fatigue during monotonous tasks and more composure under pressure. The peptide itself is measurable in the body for only minutes, but the processes it sets off keep running for hours to days. That is why Semax needs neither a steady blood level nor round-the-clock dosing, one to three doses across the day cover it.

At about 814 daltons Semax is a small, water-soluble peptide. The nasal lining is thin and richly supplied with blood. Shevchenko and colleagues (Bioorganicheskaia Khimiia 2006) tracked tritium-labelled Semax after nasal dosing in rats and found the peptide in the brain just two minutes later, about 80 percent of it still intact. After that things moved fast: peptidases take Semax apart. The fragment Pro-Gly-Pro soon dominated the tissue samples. Part of the dose crosses the lining into the blood, part travels from the olfactory region directly towards the brain. Whatever runs down the throat is digested.

What is interesting is that the route shapes the effect profile. Manchenko and colleagues (2010) compared nasal dosing with injection into the abdominal cavity in rats: nasally, Semax improved learning more strongly at a lower amount, while the pain-dampening effect of the injection did not appear nasally at all. For the nootropic use that argues for the nose, not against it. In humans, Lebedeva and colleagues (2018) showed with resting-state fMRI that 5 and 20 minutes after nasal 1 percent Semax the default mode network in the medial frontal cortex changes measurably. Under placebo it does not. Nasal dosing demonstrably reaches the human brain.

In practice: before first use, press the pump 2 to 3 times into the air until a fine mist appears. Gently clear your nose first, keep your head upright, aim the nozzle slightly outward toward the nasal wall and not at the septum, breathe in calmly while spraying, do not sniff hard. Do not blow your nose for 10 to 15 minutes afterwards. Two sprays in quick succession into the same nostril tend to run down the throat rather than work twice, so with two sprays use one per nostril or space them out.

Semax has three decades of research behind it, almost all of it from Russia. That deserves honest framing. Preclinically the base is solid: the BDNF and TrkB induction in the hippocampus (Dolotov 2006), the rapid uptake after nasal dosing (Shevchenko 2006), the advantage of the nose over injection for learning (Manchenko 2010) and a series of stroke models in which Semax shifts gene expression toward less inflammation and better vascular protection. These studies explain why Semax works, not how strongly it works in a healthy person.

Clinically the picture is split. For stroke there are patient studies with hundreds of participants, most recently Gusev and colleagues (2018) with 110 patients in rehabilitation, where 6mg per day nasally raised blood BDNF levels and sped up everyday recovery. For nootropic use in healthy people the evidence is thinner: the fMRI study by Lebedeva and colleagues (2018) shows in 24 healthy adults that nasally given Semax changes the default mode network within minutes, but says nothing about whether anyone works better because of it. Large, blinded studies on focus and memory in healthy people to Western standards are still missing.

What that means for you: the mechanism is well described and nasal uptake in humans is documented. The everyday effects rest on small studies, Russian treatment experience and user reports. That is the expectation to start with. The studies with links are in the source block below.

In the Russian patient studies, including older people, Semax is described as well tolerated with few side effects. That matches user reports. The nose itself is affected most often: mild burning, dryness or a tingling right after spraying, occasionally a bit more secretion. This usually settles within the first days. If irritation persists or the nose bleeds, pause and aim the nozzle further outward toward the nasal wall next time.

Because Semax is activating, the other observations come from that direction: head pressure, mild restlessness or a sense of being too wired, plus a shifted or shallower sleep with late use. That is the reason for the rule of placing the last spray no later than early afternoon. Anyone taking stimulants should know that in animal work Semax markedly amplified dopamine release under amphetamine, so the combination is not trivial.

The Russian label advises against Semax in acute psychotic states, anxiety disorders with marked tension, a history of seizures as well as during pregnancy and breastfeeding, among others. Serious side effects are not described in the literature, but data on very long continuous use are limited and the studies come almost entirely from one country. So phases rather than continuous use. For anything beyond an irritated nose, stop and get it checked.

The spray belongs in the fridge at 2 to 8 degrees, upright, capped and protected from light, for example in its outer packaging. Do not freeze it, freeze-thaw cycles can damage the peptide and the pump. A few hours at room temperature in the mail or in a bag are harmless, but the bottle should not sit warm or in the sun for long.

Semax is a small peptide whose chain end is shielded from enzymes by Pro-Gly-Pro. Its weak spot is the methionine at the start of the chain, which can oxidise in solution over time. The warmer, brighter and more air-exposed the bottle, the faster that happens. Kept cold and dark the solution stays stable for several months. In practice the bottle is empty after 2 to 7 weeks at 1 to 3 sprays per day anyway, within the phase it is meant for. If you pause for longer, leave the spray in the fridge and pump once into the air before the next use.

The 0.4ml of bacteriostatic water does bring a little benzyl alcohol along, but diluted into 5.4ml it offers no reliable protection against germs. So hygiene matters more than anything else: wipe the nozzle with a clean tissue after each use, put the cap back on, place the nozzle only just inside the nostril and do not push it in deep. A bottle is personal, do not share it. If the solution turns gel-like, lumpy or smells different, stop using it. Slight cloudiness on its own is not a reason.